Scientia Potentia Est

Romesh Collins

, , , , , ,
No comments on Understanding PROTACs: A New Era in Drug Development

Understanding PROTACs: A New Era in Drug Development

Featured below is an article I wrote for Charles River Laboratories exploring the field of Proteolysis Targeting Chimeras (PROTACs™). In this piece, I discuss how these innovative bifunctional molecules work by recruiting E3 ligase enzymes to target specific proteins for degradation, potentially opening new doors for treating cancer, autoimmune disorders, and neurodegenerative diseases.

The article covers the unique structure of PROTACs™, their advantages over traditional small-molecule inhibitors, bioanalytical challenges, and their presence in clinical trials. Since publication, the field has continued to evolve, but PROTACs™ remain an exciting frontier in drug development with the potential to address previously “undruggable” targets.

Read the full article here.

Romesh Collins's avatar

Posted by:

Romesh Collins

I’m a strategic marketing leader driven by an unwavering passion for scientific decision-making, data analysis, and the art of effective communication. Throughout my career in life sciences and biotechnology, I have crafted global marketing strategies that not only drive demand but also shape industry narratives and create lasting value for businesses and customers. Welcome to my corner of the digital world – a vibrant space where knowledge transcends traditional boundaries. Here, I invite you to explore science, business, history, and the arts through my unique analytical lens.

Leave a comment